Introduction
============

The retina is an experimentally tractable preparation for understanding how nervous systems abstract complex information from the environment, including information about object motion, orientation, and permanence under different light conditions ([@B40]; [@B27]; [@B8]). Retinal neurons comprise three major classes: the primary sensory cells which include rods and cones; interneurons which include horizontal, bipolar and amacrine cells (ACs); and, the output neurons, retinal ganglion cells (RGCs), that project to retino-recipient areas in the brain.

A diversity of cell types in the retina provides the infrastructure necessary for visual signal processing. There are at least 40 types of RGCs, 50 types of ACs, 14 types of bipolar cells, 2 types of horizontal cells, and 3 types of glial cells ([@B27]; [@B8]). Each of the RGC types is tuned to respond best to different and sometimes complex features in a visual scene ([@B27]; [@B35]; [@B4]). The unique response properties of each RGC type originates from the interplay between excitation and inhibition centered around the RGC dendrites. An RGC type receives excitatory inputs from a subset of the cone bipolar cell types and inhibitory inputs from a subset of AC types ([@B27]; [@B8]). Due to the large number of cell types involved and their extensive process ramifications in the innerplexiform layer (IPL), a connectivity diagram containing both functional and anatomical information for the bipolar and AC circuits that feed into each ganglion cell type is unresolved.

Physiological, molecular, and genetic approaches have been used to gain access to specific amacrine and ganglion cell types in order to systematically study their organization and function. One of the most prominent approaches involves the use of genetically modified mouse lines that heritably express transgenes such as GFP or Cre under gene specific promoters ([@B14]; [@B38]; [@B17]). Recently, we analyzed more than 20 Cre drivers that allowed us to distinguish and access more than half of the cell types in the retina ([@B41]). While "one-component" transgenic lines ([@B2]) have greatly facilitated the study of retinal function, a persistent problem is that nearly every Cre driver or GFP line targets multiple cell types ([@B41]; [@B26]). This multiplicity makes functional studies more difficult by degrading the specificity of broadly applied optogenetic and chemogenetic manipulations. There is a pressing need to further restrict retinal transgene expression to a few or even one neuron type in order to obtain unambiguous information about processing.

We employed an intersectional strategy in which transgene expression is defined by the combination of two recombinases each driven by a distinct gene promoter ([@B9]; [@B25]; [@B15]). To date, the most commonly used intersectional combination is the Cre and Flp dual-recombinase system that simultaneously uses both Cre/loxP and Flp/FRT combination to remove a STOP cassette or to reverse a double-floxed inverse open reading frame (DIO/FLEX) ([@B3]; [@B39]). Either editing event can lead to the activation of a reporter/effector solely in cells expressing both Cre and Flp recombinases (**Figure [1A](#F1){ref-type="fig"}**). A prerequisite for the efficient application of an intersectional strategy is to identify the candidate Cre and Flp drivers for crossing. The preferred pair of Cre and Flp drivers should be controlled by different promoters that have overlapping expression patterns in the cells of interest. To facilitate this approach, we have characterized the retinal expression patterns in available Cre and Flp drivers. Based on the individual expression patterns, we crossed lines to produce restricted intersectional expression (**Figure [1B](#F1){ref-type="fig"}**). A rational extension of this approach can make use of retinal transcriptomic information to design additional Cre and Flp drivers.

![Intersectional strategy with Cre/Flp dual recombinase. **(A)** Schematic diagram of the intersectional strategy with Cre/Flp dual recombinase. The Cre driver line uses gene specific promoter 1, the Flp driver line uses gene specific promoter 2, and the double reporter uses a ubiquitous promoter (left). Expression of tdTomato in the reporter line (*Ai65*) is prevented by lox- and frt-flanked STOP cassettes. Following removal of both STOP cassettes, tdTomato is expressed in the cells that are in the overlap or "intersection" of the two populations of neurons targeted by either the Cre driver or the Flp driver (right). **(B)** Intersectional strategies provide flexibility for targeting specific cell types. Each Flp line can be crossed with many Cre lines to create multiple intersections.](fncir-12-00066-g001){#F1}

The intersectional approach has been recently used in the nervous system to anatomically map and functionally study genetically-defined subpopulations of neurons ([@B25]; [@B15]), but its effectiveness in retina has not been demonstrated. Here, we screened and analyzed seven new Flp drivers for expression patterns in the retina, lateral geniculate nucleus (LGN), and superior colliculus (SC). We then created and characterized multiple combinational mouse lines by selective cross breeding of Flp and Cre drivers. Our results demonstrate that an intersectional recombination-based system is a powerful tool for increasing the specificity of cell-type targeting in the retina.

Materials and Methods {#s1}
=====================

Animals
-------

All the Flp drivers, Cre drivers and reporters were obtained directly from Jackson Laboratory or individual investigators (**Table [1](#T1){ref-type="table"}**). Adult mice (5--6 weeks old) of either sex were used for experiments. All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health. All procedures for testing and handling were approved by the Institutional Animal Care and Use Committee of Northwestern University. Cre expression in the *CAGGCreER/Pvalb-FlpE* and *UBC-CreER2/Sst-FlpO* mice relied on "leakiness" without tamoxifen induction. To enhance Cre expression in the *UBC-CreER2*/*Vip-FlpO* mice, single injection of tamoxifen (20 μg, Sigma) was applied intraperitoneally, and retinas were collected after 2--3 days.

###### 

Mouse lines used in this study.

  Mouse line                Full name                                          Source
  ------------------------- -------------------------------------------------- --------------------------
  *Pvalb-FlpE*              B6.Cg-*Pvalb^tm2.1(FLPe)Hze^*/J                    JAX 021191
  *Sst-FlpO*                *Sst^tm3.1(flpo)Zjh^*/J                            JAX 028579
  *Vip-FlpO*                *Vip^TM2.1(flpo)Zjh^*/J                            JAX 028578
  *Slc32a1-FlpO*            B6.Cg-Slc32a1^TM1.1(flpo)Hze^/J                    JAX 029591, Hongkui Zeng
  *Rorb-FlpO*               B6.Cg**-***Rorb^TM3.1(flpo)Hze^*/J                 JAX 029590
  *Nkx2-FlpO*               Nkx2-1^tm2.1(flpo)Zjh^/J                           JAX 028577
  *Dlx5/6-FlpE*             Tg(mI56i-flpe)39Fsh/J                              JAX 010815
  *CMV-Cre*                 B6.C-Tg(CMV-cre)1Cgn/J                             JAX 006054
  *Vglut2-Cre*              Slc17a6^tm2(cre)Lowl^/J                            JAX 016963
  *Slc32a1-Cre(VGAT-Cre)*   Slc32a1^tm2(cre)Lowl^/J                            JAX 016962
  *UBC-CreER2*              B6.Cg-Ndor1^Tg(UBC-cre^**^/^**^ERT2)1Ejb^/1J       JAX 007001
  *CAGGCre-ER*              B6.Cg-Tg(CAG-cre/Esr1^∗^)5Amc/J                    JAX 004682
  *Cck-Cre*                 Cck^tm1.1(cre)Zjh^/J                               JAX 012706
  *Pcp2-cre*                B6.129-Tg(Pcp2-cre)2Mpin/J                         JAX 004146
  *Crh-Cre*                 B6(Cg)-*Crh^TM1(cre)Zjh^*/J                        JAX 012704
  *Cart-Cre*                B6;129S*-Cartpt^TM1.1(cre)Hze^*/J                  JAX 028533
  *Penk-Cre*                B6;129S*-Penk^tm2(cre)Hze^*/J                      JAX 025112
  *Ai9*                     B6.Cg-Gt(ROSA)26Sor^tm9(CAG-tdTomato)Hze^/J        JAX 007909
  *Ai65*                    B6;129S-Gt(ROSA)26Sor^tm65.1(CAG-tdTomato)Hze^/J   JAX 021875

JAX, the Jackson Laboratory

.

Immunohistochemistry and Imaging
--------------------------------

For immunohistochemistry in the retina, mice were euthanized, and eyes were fixed with 4% paraformaldehyde for 1h and then retinas were dissected. Retinas were washed with a modified phosphate buffer (PB) containing 0.5% Triton X-100 and 0.1% NaN~3~, pH 7.4, and then blocked for 2 days in modified PB containing 3% donkey serum. After that, retinas were incubated with primary antibody for 5 days and secondary antibody for 2 days at 4°C.

To label retinorecipient regions, 2 μl of cholera toxin B conjugated to Alexa Fluor 488 (CTb-488: 1% in saline; Thermo Fisher Scientific) was injected into each eye. After 24 h, the animal was perfused transcardially with 4% paraformaldehyde, and the brain was removed for post-fixed for 3--5 d at 4°C. After washing with phosphate buffered saline, the brains were sectioned at 80 μm in a cryostat. Immunohistochemistry proceeded as for the retina, except that incubation times with primary and secondary antibody were reduced to 2 and 1 day respectively.

The primary antibodies used were as follows: rabbit anti-RFP (1:1000, Rockland 600-401-379), chicken anti-RFP Biotin conjugated (1:200, Rockland 600-906-379), guinea pig anti-RBPMS (1:500, PhosphoSolutions 1832-RBPMS), mouse anti-AP2 (3 μg/ml, DSHB 3B5), goat anti-Osteopontin (1:500, R&D 441-OP-050), rabbit anti-CART (1:1000, Phoenix pharmaceuticals H-003-62), goat anti-FOXP2 (1:500, Abcam ab1307), rabbit anti-melanopsin (1:1000, Advanced Targeting Systems AB N38), goat anti-choline acetyltransferase (1:500, Millipore AB144P), rabbit anti-GABA (1:2000, Sigma-Aldrich A2052), goat anti- GLYT1 (1:25, Santa Cruz Biotechnology sc-16703), rabbit anti-VIP (1:1000, ImmunoStar 20077), rat anti-SST (1:10, Millipore MAB354). Secondary antibodies were conjugated to Alexa Fluor 488 (Invitrogen), Cy3 (Jackson ImmunoResearch), or Cy5 (Jackson ImmunoResearch). All secondary antibodies were used at a dilution of 1:200.

Imaging and Morphological Analysis
----------------------------------

Images were captured with a Zeiss LSM-510 Meta confocal microscope and processed with LSM Image software, Image J and Photoshop. Flat-mount images of retinas were acquired with either a Plan-Neofluar 25x/0.8 Imm Corr objective or a Plan-Apochromat, 63×/1.4 oil objective. Z-stack images of tdTomato-labeled cells and ChAT antibody-labeled ChAT bands were obtained with a Plan-Apochromat, 63×/1.4 oil objective at 0.25 μm intervals. Brain sections were imaged with a Plan-Neofluar 10x/0.3 air objective, with enlarged views imaged with a Plan-Neofluar 25x/0.8 Imm Corr objective.

To measure the size of the dendritic field, a convex polygon was drawn connecting the outermost tips of the dendrites, and the area within this contour was measured. The diameter of the dendritic field was calculated from the measured area by assuming the dendritic field is circular. Soma diameter was calculated in the same way. To measure the level of stratification of ACs and RGCs, a rectangle representing the region of interest (∼200 μm × 70 μm) was placed near the center of a dendritic field. The image data within the ROI at each level of the *z*-stack was projected onto the *x*-axis. The stratification levels were determined from the upper and lower boundaries of tdTomato-labeled arbors relative to the choline acetyltransferase (ChAT)-positive bands (60 and 27% of the IPL) in XZ plane. For wide-field ACs, the same procedure was repeated on the middle and distal parts of the dendritic field or "axon-like" arbors to verify the consistency of stratification in different parts of the cell. Data are presented as mean ± SD.

Results
=======

General Screening Strategy
--------------------------

While Cre drivers have been screened for their expression patterns in the retina ([@B17]; [@B23]; [@B41]; [@B26]), no Flp drivers have been screened. We recently acquired seven Flp drivers: *Pvalb-FlpE*, *Slc32a1-FlpO*, *Sst-FlpO*, *Vip-FlpO*, *Nkx2-FlpO*, *Dlx5/6-FlpE* and *Rorb-FlpO*. Our goals in this study were three-fold: first, to characterize the amacrine and RGC expression patterns in these Flp drivers; second, to validate intersectional strategies in the retina; and third, to establish Cre/Flp combination lines that achieve increased specificity for subsequent anatomical and functional studies.

Our screening proceeded in three steps. The first step was to obtain the expression patterns of FLP in the retina, achieved by crossing Flp drivers with a Cre/Flp double-dependent *Ai65* reporter and a ubiquitous Cre driver (*CMV-Cre*). In the second step, FLP expression in RGCs or ACs was separated based on the differential presence/absence of characteristic vesicular neurotransmitter transporters. Specifically, we took advantage of the fact that glutamate transporter 2 (VGLUT2) is expressed in RGCs but not in ACs ([@B19]; [@B22]), whereas the vesicular inhibitory amino acid transporter (VIAAT) is expressed in ACs but not RGCs. Thereby, we isolated RGCs and ACs by crossing the Flp drivers with a *Vglut2-Cre* and *Slc32a1-Cre* drivers respectively. Finally, in the third step, single cell morphologies were analyzed in the RGC group and the AC group, and the cell types were assigned based on published work. If the labeling was too dense to resolve single cell structure, we further crossed Flp drivers with ubiquitous inducible Cre drivers such as *UBC-CreERT2* and *CAGGCre-ER*, and achieved sparse labeling by adjusting the dose of tamoxifen.

General Expression Patterns of Flp in the Retina
------------------------------------------------

The results from seven Flp drivers are summarized in **Figure [2](#F2){ref-type="fig"}**. Among the seven Flp drivers, the *Pvalb-FlpE* drove FLPe expression mainly in the GCL, with only a few cells in the INL (**Figure [2Ai](#F2){ref-type="fig"}**). These FLPe-expressing cells were exclusively RGCs, as confirmed by RBPMS immunoreactivity, a marker for RGCs ([@B33]) (**Figure [2Aii](#F2){ref-type="fig"}**). The *Sst-FlpO* driver targeted both RGCs and ACs (**Figure [2Bi](#F2){ref-type="fig"}**). In the GCL, there were both RGCs, confirmed with the RBPMS antibody (**Figure [2Bii](#F2){ref-type="fig"}**, Top) and GABAergic ACs confirmed with AP2 (Activating protein 2) and GABA antibodies (**Figures [2Biii,iv](#F2){ref-type="fig"}**, top). AP2 is a family of transcription factors that have been shown to play essential roles in development ([@B16]; [@B10]). In both mammalian and avian retinas, AP2 is exclusively expressed in postmitotic ACs, but not in other cell types ([@B7]; [@B5]). SST^+^ cells in the INL belonged to GABAergic ACs based on AP2 and GABA staining (**Figures [2Biii,iv](#F2){ref-type="fig"}**, bottom). Since, both RGCs and ACs were targeted in the *Sst-FlpO* driver, it a good preparation in which to test for the feasibility of RGCs/ACs segregation using the *Vglut2-Cre* or the *Slc32a1-Cre* in intersection (described later). The *Vip-FlpO* driver exclusively targeted ACs (**Figure [2C](#F2){ref-type="fig"}**). Consistent with the expression pattern of a *Vip-Cre* line ([@B41]), the majority of the targeted cells in the *Vip-FlpO* driver were located in the INL (**Figure [2Ci](#F2){ref-type="fig"}**, bottom). These cells were positive for both AP2 and GABA labeling (**Figures [2Cii,iii](#F2){ref-type="fig"}**), indicating that they were all GABAergic ACs. The *Slc32a1-FlpO* drove FLPo expression in almost all ACs, hence labeling density was high and widespread (**Figure [2Di](#F2){ref-type="fig"}**). Slc32a^+^ cells included both the GABAergic and non-GABAergic cells (**Figure [2Dii](#F2){ref-type="fig"}**). The non-GABAergic cells were glycinergic ACs positively stained with a GLYT1 antibody (**Figure [2Diii](#F2){ref-type="fig"}**). *Nkx2-FlpO* and the *Dlx5/6-FlpE* had very low expression in retinal cells (**Figures [2E,F](#F2){ref-type="fig"}**). Finally, *Rorb-FlpO* consistently targeted many types of bipolar cells, ACs, and RGCs, but expression levels were strongest in Müller cells (**Figure [2G](#F2){ref-type="fig"}**). Based on these results, the *Nkx2-FlpO*, *Dlx5/6-FlpE* and *Rorb-FlpO* drivers were excluded from further analysis.

![Distribution of FLP-expressing cells in 7 Flp drivers. Each Flp driver was crossed with *CMV-Cre* and *Ai65* mice. **(A)** *Pvalb-FlpE* driver. **(i)** FLPe expressing cells labeled with tdTomato (tdT, red) were observed in the GCL (top) with only a few cells in the INL (middle). Bottom: side view with ChAT (blue). **(ii)** Staining for the RGC marker RBPMS (green) confirmed that all of the tdTomato-labeled cells (tdT, red) in the GCL and the INL were RGCs. White arrows point to example cells that express RBPMS. **(B)** *Sst-FlpO* driver. **(i)** tdTomato-labeled cells were distributed in both the GCL (top) and the INL (middle). Bottom: side view with ChAT (blue).**(ii)** RBPMS staining (green). SST^+^ RGCs were found in the GCL, but not in the INL. White arrow indicates a RBPMS^+^ cell (RGC), blue arrow indicates a RBPMS^-^ cell (presumably an amacrine cell). **(iii)** An amacrine cell marker, AP-2 (green) overlaps with SST^+^ amacrine cells in both the GCL and the INL. White arrows indicate example cells that express AP2. **(iv)** GABA staining (green). White arrows indicate example cells expressing GABA. SST^+^ amacrine cells in both GCL and INL were GABAergic. **(C)** *Vip-FlpO* driver. **(i)** A majority of the targeted cells (red) in the *Vip-FlpO* driver were located in the INL (middle). Bottom: side view with ChAT (blue). These presumptive GABAergic amacrine cells were positive for both AP2 **(ii)** and GABA staining **(iii)**. **(D)** *Slc32a1-FlpO* driver. **(i)** Labeling density was high in both the GCL and INL. **(ii)** Double labeling for tdTomato (red) and GABA (green). In the GCL, ∼80% of cells were GABAergic, whereas in the INL, ∼50% of tdT cells were GABAergic. Examples of GABAergic and non-GABAergic cells (presumably glycinergic amacrine cells) are indicated by white and blue arrows, respectively.**(iii)** Vertical sections showed that tdTomato-labeled cells were either GABAergic (green, GABA staining) or glycinergic (blue, GlyT1 staining). **(E,F)** *Nkx2-FlpO driver***(E)** and *Dlx5/6-FlpE* driver **(F)** showed very little labeling in both the GCL and the INL. **(G)** *Rorb-FlpO* driver showed broad labeling in the GCL and INL, with the strongest labeling in Müller cells. Scale bar, 40 μm for flat-mount view, 10 μm for side view.](fncir-12-00066-g002){#F2}

Genetic Dissection of Individual Cell Types in Flp Drivers
----------------------------------------------------------

To provide a benchmark for judging the efficacy of the intersectional approach, we next characterized the cell types labeled in the parent Flp driver lines (**Table [2](#T2){ref-type="table"}**) with a focus on *Pvalb-FlpE*, *Sst-FlpO*, and *Vip-FlpO*.

###### 

Summary of AC and RGC types in Flp drivers.

  Flp driver       Amacrine cell types            RGC types
  ---------------- ------------------------------ ----------------------------------------------------------------------------------------------------
  *Pvalb-FlpE*     No                             on-alpha RGC, off-alpha RGC, ooDSGC, on-DSGC, F-mini-off RGC, F-mini-on RGC, sbcRGC, CRH-3, G1, G4
  *Sst-FlpO*       SST-AC1, SST-AC2, SAC          on-alpha RGC, off-alpha RGC, ooDSGC, F-mini-on RGC, F-midi-off RGC, W3, G2, G4, G14, G30
  *Vip-FlpO*       VIP-1 AC, VIP-2 AC, VIP-3 AC   No
  *Slc32a1-FlpO*   More than 95% of ACs           Very few
  *Rorb-FlpO*      Many types                     Many types
  *Nkx2-FlpO*      Low expression                 Low expression
  *Dlx5/6-FlpE*    Low expression                 Low expression

### The *Pvalb-FlpE* Driver Targets at Least 10 Types of RGCs

The most efficient way to survey cell types is to use type-specific molecular markers. We labeled PVALB^+^ RGCs with molecular markers for the following RGCs ([@B34]): Osteopontin for alpha RGCs, CART for ooDSGCs (on-off DSGCs), FOXP2 for F-RGCs, and melanopsin for ipRGCs (**Figure [3A](#F3){ref-type="fig"}**). Forty-five percent of PVALB^+^ RGCs were alpha RGCs, 16% were ooDSGCs, 13% were F-RGCs, and none were melanopsin positive ipRGCs (**Figure [3B](#F3){ref-type="fig"}**). About 26% of PVALB^+^ RGCs were not labeled by any of the four antibodies. In order to define the subtypes of the unlabeled cells, we applied established cell morphological criteria. We crossed the Pvalb-FlpE driver with a CAGGCre-ER driver and Ai65 reporter line. The CAGGCre-ER driver has a small amount of "leaky" Cre expression in the absence of tamoxifen, which allowed us to visualize individual cells for single-cell reconstruction. In addition to alpha RGCs, ooDSGCs, F-RGCs (**Figures [3Ci](#F3){ref-type="fig"}--[v](#F3){ref-type="fig"}**), the analysis of single cell morphologies revealed that Pvalb-FlpE targeted at least 5 more RGC types that resemble on-DSGCs, sbcRGCs, CRH-3 RGCs ([@B41]), G1 RGCs and G4 RGCs ([@B4]). Examples of single cell morphologies representing each RGC type are shown in **Figures [3Cvi](#F3){ref-type="fig"}--[x](#F3){ref-type="fig"}**. It has been reported that the Pvalb-Cre driver shows differential labeling across the retina ([@B4]). In this study, the cells were analyzed across the entire retina instead of any preferred locations.

![The *Pvalb-FlpE* driver targeted multiple RGC types. **(A)** The *Pvalb-FlpE* driver was crossed with *CMV-Cre* and *Ai65* mice. Immunostainings were performed by using antibody markers for 4 different RGC types: Osteopontin for alpha RGCs, CART for ooDSGCs, FOXP2 for F-RGCs, and melanopsin for ipRGCs. Scale bar, 20 μm. **(B)** Proportions of RGC types targeted in the *Pvalb-FlpE* driver. *n* = 6 retinas from 6 animals (6 litters). **(C)** RGC types extracted from *CAGGCre-ER;Pvalb-FlpE;Ai65* retinas without tamoxifen administration. Flat-mount view (top) and side view (bottom) with ChAT (blue) labeling. Scale bar: 50 μm for the flat-mount view, 10 μm for the side view.](fncir-12-00066-g003){#F3}

### The Sst-FlpO Driver Targets at Least 10 Types of RGCs and 3 Types of ACs

Since the Sst-FlpO driver expressed transgenes in both RGCs and ACs (**Figure [2B](#F2){ref-type="fig"}**), we tested whether we could separate RGCs from ACs by crossing Sst-FlpO mice with Vglut2-Cre and Slc32a-Cre mice, respectively. As predicted, all the AC labeling was removed and only RGCs remained labeled in the Vglut2-Cre/Sst-FlpO cross (**Figure [4Ai](#F4){ref-type="fig"}**). The labeled RGCs were spaced far apart, enabling us to perform single-cell reconstruction. In the Slc32a-Cre/Sst-FlpO cross, only ACs remained labeled, including cells in both INL and GCL (**Figure [4Aii](#F4){ref-type="fig"}**). AC labeling was dense and required further segregation.

![The *Sst-FlpO* driver targeted both RGCs and ACs. **(A)** **(i)** To identify targeted RGCs, the *Sst-FlpO* driver was crossed with *Vglut2-Cre* and *Ai65* reporter mice. **(ii)** To identify targeted amacrine cells, the *Sst-FlpO* driver was crossed with *Slc32a1-Cre* and *Ai65* mice. Scale bar, 50μm. **(B)** Staining for RGC markers (green). RGC constituents were probed with antibodies against Osteopontin, CART, FOXP2 and melanopsin in the *Vglut2-Cre*;*Sst-FlpO;Ai65* retinas. Scale bar, 20 μm. **(C)** Proportions of RGC types targeted in the *Sst-FlpO* driver. *n* = 7 retinas from 7 animals (6 litters). **(D)** Individual RGC types extracted from the *Vglut2-Cre*;*Sst-FlpO;Ai65* retinas. Flat-mount views (top) and side views (bottom) with ChAT (blue). Scale bar: 50 μm for the flat-mount view, 10 μm for the side view. **(E--G)** Amacrine cell types extracted from the *UBC-CreER2;Sst-FlpO;Ai65* retinas, without tamoxifen administration. **(E)** Representative images of an SST-1 AC. **(i)** Flat-mount view of the soma and surrounding processes. **(ii)** Side view of the soma and surrounding "dendrite-like" and "axon-like" processes. **(iii)** Axon-like processes traveled across the IPL and ended at the INL border **(iv)**. An SST-1 AC was co-labeled with antibodies against GABA **(v)** and SST **(vi)**. **(F)** A starburst amacrine cell (SAC) in the GCL. Flat-mount view (top) and side view (bottom) with ChAT (blue). **(G)** SST-2 AC. Flat-mount view of the soma and surrounding processes. **(ii)** Side view of the soma and surrounding dendrite-like (white arrow) and axon-like processes (green arrow). **(iii)** Axon-like process end at the INL border. An SST-2 AC was co-labeled with antibodies against GABA **(iv)** and SST **(v)**. Scale bar for **(E--G)**: 50 μm for the flat-mount view, 10 μm for the side view.](fncir-12-00066-g004){#F4}

To characterize the distribution of RGC types in the *Vglut2-Cre*/*Sst-FlpO* retina, we first labeled SST^+^ RGCs with antibodies against Osteopontin, CART, FOXP2 and melanopsin (**Figure [4B](#F4){ref-type="fig"}**). Unlike in the *Pvalb-FlpE* driver, alpha RGCs only accounted for 20% of SST^+^ RGCs, ooDSGCs accounted for 26%, and F-RGCs accounted for 8% of SST^+^ RGCs (**Figure [4C](#F4){ref-type="fig"}**). No SST^+^ RGCs was labeled by the antibody to melanopsin. Forty-six percent of SST^+^ RGCs were unidentified by the antibodies. Single-cell reconstruction revealed that, in addition to alpha RGCs, ooDSGCs, and F-RGCs (**Figures [4Di](#F4){ref-type="fig"}--[v](#F4){ref-type="fig"}**), the *Sst-FlpO* driver targeted at least 5 more RGC types. Their morphologies strongly resembled those of W3, G2, G4, G14, and G30 ([@B4]) (**Figures [4Dvi](#F4){ref-type="fig"}--[x](#F4){ref-type="fig"}**). Although alpha RGCs were the dominant RGC in the *Pvalb-FlpE* driver, RGCs in the *Sst-FlpO* driver were more evenly distributed among at least 10 RGC types.

Since AC labeling was still quite dense in the *Slc32a-Cre*/*Sst-FlpO* line, we identified ACs in the *Sst-FlpO* driver by crossing it with an inducible Cre driver, *UBC-CreERT2*, which facilitated sparse labeling. We ignored labeled RCGs in the *UBC-CreERT2*/*Sst-FlpO* retina and instead identified three types of ACs, two in the GCL and one in the INL. The first AC type in the GCL was similar to the SST-1 AC identified in the *Sst-Cre* driver ([@B41]). It had a soma ∼13 μm (12.8 ± 1.3 μm) in diameter and gave rise to thick "dendrite-like" processes and a long, fine axon-like process (**Figure [4Ei](#F4){ref-type="fig"}**). The dendrite-like arbors ramified at the GCL border (**Figure [4Eii](#F4){ref-type="fig"}**), while the axon-like arbor started off near the GCL border and then traversed the width of the IPL and ended in a ramification at the INL border (**Figures [4Eii](#F4){ref-type="fig"}--[iv](#F4){ref-type="fig"}**). SST-1 ACs were GABAergic (**Figure [4Ev](#F4){ref-type="fig"}**) and labeled with an antibody to SST (**Figure [4Evi](#F4){ref-type="fig"}**). The second AC type in the GCL was a displaced starburst AC (**Figure [4F](#F4){ref-type="fig"}**), which was also observed in the *Sst-Cre* driver ([@B41]). The AC type in the INL (named SST-2 AC) had a soma around 11 μm (10.9 ± 1.2 μm) in diameter, and gave rise to 2--3 dendrite-like processes (**Figure [4Gi](#F4){ref-type="fig"}**) that branched and ramified at the GCL border (**Figure [4Gii](#F4){ref-type="fig"}**), and 1-2 axon-like processes that remained at the INL border (**Figure [4Giii](#F4){ref-type="fig"}**). SST-2 ACs were GABAergic (**Figure [4Giv](#F4){ref-type="fig"}**) and positive for SST antibody labeling (**Figure [4Gv](#F4){ref-type="fig"}**).

### The *Vip-FlpO* Driver Targets 3 Types of ACs

To segregate cell types in the Vip-FlpO driver, we crossed it with the UBS-CreERT2 driver and achieved sparse labeling with a low dose of tamoxifen. The Vip-FlpO driver targeted FLPo expression in three AC types, consistent with the Cre expression pattern described in the Vip-Cre driver ([@B1]; [@B28]; [@B31]). The first type was a wide-field bistratified AC previously named VIP-1 ([@B41]; [@B1]). VIP-1 ACs have somata (11.2 ± 1.1 μm in diameter) located in the INL with dendrites that ramified in two layers (**Figure [5Ai](#F5){ref-type="fig"}**): the ON dendrites ramified between the ON ChAT band and the GCL (75.8% ± 3.5% of the IPL) and the OFF dendrites ramified between the OFF ChAT band and the INL (12.9% ± 1.6% of the IPL). Many of the cells had a long process or "tails" that extended at least 200 μm from the soma (**Figure [5Ai](#F5){ref-type="fig"}**). The ON and OFF dendritic fields (excluding the "tails") were 201 ± 27 μm and 178 ± 36 μm in diameter, respectively. The second type was a monostratified AC named VIP-2 in previous studies ([@B1]; [@B31]). The cell soma was located in the INL and its dendrites ramified in a thick band between 41.8 ± 3.5% and 65.8% ± 0.2% in the IPL covering the ON ChAT band (**Figure [5Bi](#F5){ref-type="fig"}**). The dendritic field of the VIP-2 AC was 100 ± 21 μm in diameter. Unlike VIP-1 and VIP-2 ACs, the third AC type (named VIP-3 ([@B1]; [@B31])) was a displaced AC with its soma located in the GCL. Its dendrites ramified near the GCL (**Figure [5Ci](#F5){ref-type="fig"}**). The dendritic field of the VIP-3 AC was 221 ± 43 μm in diameter. All three types of VIP ACs were GABAergic (**Figures [5Aii,Bii,Cii](#F5){ref-type="fig"}**) and labeled with an antibody to VIP (**Figures [5Aiii,Biii,Ciii](#F5){ref-type="fig"}**). **Table [2](#T2){ref-type="table"}** summaries the AC and RGC types in Flp drivers.

![The *Vip-FlpO* driver targeted 3 types of ACs. The *Vip-FlpO* driver was crossed with *UBC-CreER2* and *Ai65*, 20 μg tamoxifen was administered to achieve sparse labeling of ACs. Representative images for VIP-1 AC **(A)**, VIP-2 AC **(B)**, and VIP-3 AC **(C)** are shown in flat-mount view (top) and side view (bottom) with ChAT (blue) in **(i)**. Arrow in **(Ai)** shows the "tail" of the VIP-1 AC. Sections were co-labeled with antibodies against GABA (green) **(ii)** and VIP (green) **(iii)**. Scale bar: 25 μm for flat-mount view, 10 μm for side view.](fncir-12-00066-g005){#F5}

Further Intersectional Strategies to Confine Retinal Cell Subpopulations
------------------------------------------------------------------------

To validate the feasibility of using Cre/Flp intersections to limit expression to a small subset or even one neuronal type in the retina, we selectively crossed pairs of Cre and Flp drivers showing overlap in expression patterns of RGCs or ACs (**Figure [6](#F6){ref-type="fig"}** and **Table [3](#T3){ref-type="table"}**).

![Intersectional strategies to restrict labeling of retinal cell subpopulations. **(A)** *Cck-Cre* driver alone and in intersection with the *Pvalb-FlpE* driver. **(i,ii)** Distribution of tdTomato-labeled cells in the GCL **(i)** and the INL **(ii)** in the *Cck-Cre* driver crossed with the *Ai9* reporter line. **(iii,iv)** Distribution of tdTomato-labeled cells from the *Cck-Cre;Pvalb-FlpE;Ai65* intersection. **(v,vi)** Examples of individual cell types within the *Cck/Pvalb* intersection. Flat-mount view (top) and side view (bottom) with ChAT (blue). **(vii,viii)** Cell labeling density in the *Cck-Cre* and the *Cck-Cre/Pvalb-FlpE* intersection for the GCL **(vii)** or the INL **(viii)**. *n* = 6 retinas from 6 animals (4 litters) for the *Cck-Cre;Ai9. n* = 6 retinas from 6 animals (5 litters) for the *Cck-Cre;Pvalb-FlpE;Ai65.* ^∗^*p* \< 0.05, two-tailed *t*-test. **(B)** *Pcp2-Cre* driver alone and in intersection with the *Pvalb-FlpE* driver. **(i,ii)** labeling of *Pcp2-Cre* mice by crossing with the *Ai9* reporter. **(iii,iv)** Intersection of *Pcp2-Cre* and *Pvalb-FlpE* in the *Ai65* reporter. **(v,vi)** Flat mount views (top) and side views (bottom) of the cell types within the *Pcp2/Pvalb* intersection. **(vii,viii)** Cell labeling density in the *Pcp2-Cre* and the *Pcp2-Cre/Pvalb-FlpE* intersection for the GCL **(vii)** or the INL **(viii)**. *n* = 6 retinas from 6 animals (4 litters) for the *Pcp2-Cre;Ai9. n* = 6 retinas from 6 animals (6 litters) for the *Pcp2-Cre;Pvalb-FlpE;Ai65*. ^∗^*p* \< 0.05, two-tailed *t*-test. **(C)** *Crh-Cre* driver alone and in intersection with the *Pvalb-FlpE* driver. **(i,ii)** *Crh-Cre* driver expression as reported by *Ai9* mice. **(iii,iv)** Intersection of *Crh-Cre* and *Pvalb-FlpE* in the *Ai65* reporter. **(v,vi)** Example images of flat mount views (top) and side views (bottom) of the cells within the *Crh/Pvalb* intersection. **(vii,viii)** Comparing cell labeling density in the *Crh-Cre* and the *Crh-Cre/Pvalb-FlpE* intersection for the GCL **(vii)** or the INL **(viii)**. *n* = 7 retinas from 7 animals (5 litters) for the *Crh-Cre;Ai9. n* = 7 retinas from 7 animals (5 litters) for the *Crh-Cre;Pvalb-FlpE;Ai65*. ^∗^*p* \< 0.05, two-tailed *t*-test. **(D)** *Cck-Cre* driver alone and *Cck-Cre/Slc32a1-FlpO* intersection. **(i,ii)** *Cck-Cre* driver crossed with the *Ai9* reporter. **(iii,iv)** Intersection of *Cck-Cre* and *Slc32a1-FlpO* reported in *Ai65* mice. **(v)** *Cck-Cre/Slc32a1-FlpO* intersection (red) in the GCL counter-stained with an antibody against ChAT (blue). **(vi,vii)** Cell labeling density in the *Cck-Cre* and the *Cck-Cre/Slc32a1-FlpO* intersection for the GCL **(vi)** or the INL **(vii)**. *n* = 6 retinas from 6 animals (5 litters) for the *Cck-Cre;Ai9. n* = 6 retinas from 6 animals (5 litters) for the *Cck-Cre;Slc32a1-FlpO;Ai65*. ^∗^*p* \< 0.05, two-tailed *t*-test. **(E)** *Cart-Cre* driver alone and in intersection with *Pvalb-FlpE* or *Slc32a1-FlpO*. **(i,ii)** *Cart-Cre* driver with *Ai9* reporter. **(iii,iv)** *Cart-Cre/Pvalb-FlpE* intersection removed labeling from amacrine cells. **(v,vi)** *Cart-Cre/Slc32a1-FlpO* intersection removed labeling from RGCs. **(vii)** Cell labeling density in *Cart-Cre* alone, *Cart-Cre/Pvalb-FlpE* intersection, and *Cart-Cre/Slc32a1-FlpO* intersection for the GCL (dark gray) or the INL (gray). *n* = 8 retinas from 8 animals (5 litters) for the *Cart-Cre;Ai9. n* = 8 retinas from 8 animals (6 litters) for the *Cart-Cre;Pvalb-FlpE;Ai65. n* = 8 retinas from 8 animals (6 litters) for the *Cart-Cre;Slc32a1-FlpO;Ai65*. ^∗^*p* \< 0.05, two-tailed *t*-test. **(F)** *Penk-Cre* driver alone and *Penk-Cre* /*Sst-FlpO* intersection. **(i,ii)** *Penk-Cre* driver with *Ai9* reporter. **(iii,iv)** Intersection of *Penk-Cre* and *Sst-FlpO* in the *Ai65* reporter. **(v,vi)** Example images of individual cell types within the *Penk/Sst* intersection. Flat-mount view (top) and side view (bottom) with ChAT (blue). **(vii,viii)** Cell labeling density in the *Penk-Cre* and the *Penk/Sst* intersection for the GCL **(vii)** or the INL **(viii)**. *n* = 7 retinas from 7 animals (5 litters) for the *Penk-Cre;Ai9. n* = 7 retinas from 7 animals (5 litters) for the *Penk-Cre;Sst-FlpO;Ai65.*^∗^*p* \< 0.05, two-tailed *t*-test. Scale bar, 20 μm for flat-mount view, 10 μm for side view.](fncir-12-00066-g006){#F6}

###### 

Intersectional strategies to restrict retinal cell subpopulations.

  Flp driver                Bipolar cells   Amacrine cells                 RGCs
  ------------------------- --------------- ------------------------------ -----------------------------------------------
  *Cck-Cre*                 Yes             Yes                            ooDSGCs, sbcRGCs, on-alpha RGCs, etc.
  *Cck-Cre/ Pvalb-FlpE*     No              No                             on-alpha RGCs (80%), G4 (20%)
  *Pcp2-Cre*                Yes             No                             m-BGCs , s-BGCs, b-BGCs, on-DSGCs and ooDSGCs
  *Pcp2-Cre/Pvalb-FlpE*     No              No                             ooDSGCs (2/3), on-DSGCs (1/3)
  *Crh-Cre*                 No              CRH-1 AC, CRH-2 AC, CRH-3 AC   off-alpha RGCs, JAM-B RGCS, CRH-3 RGCs
  *Crh-Cre/ Pvalb-FlpE*     No              No                             off-alpha RGCs (80%), CRH-3 RGCs (20%)
  *Cck-Cre*                 Yes             Yes                            ooDSGCs, sbcRGCs, on-alpha RGCs, etc.
  *Cck- Cre/Slc32a-FlpO*    No              Yes                            No
  *Cart-Cre*                No              Yes                            ooDSGCs
  *Cart-Cre/Pvalb-FlpE*     No              No                             ooDSGCs
  *Cart-Cre/Slc32a1-FlpO*   No              Yes                            No
  *Penk-Cre*                No              Multiple types                 Multiple types
  *Penk-Cre/Sst-FlpO*       No              SST-2 AC                       G14

### *Pvalb-FlpE* Driver for Targeting Specific RGC Types

Since the *Pvalb-FlpE* driver exclusively targeted RGC types, we reasoned that this line could provide a useful filter to remove non-RGC types in the Cre/Flp intersection. This idea was demonstrated in several examples. The first example was a *Cck-Cre*/*Pvalb-FlpE* intersection. In the *Cck-Cre* line, Cre expression was observed in bipolar, amacrine, ganglion, and Müller cells ([@B41]). Bipolar cells made up more than half of the labeled cells in the INL, with the rest being ACs and a small number of Müller cells (**Figure [6Aii](#F6){ref-type="fig"}**). The GCL contained both labeled ACs and RCGs (**Figure [6Ai](#F6){ref-type="fig"}**) including the following types: starburst ACs, ooDSGCs, sbcRGCs, on-alpha RGCs ([@B41]), and other RGC types. Thus, combining the *Cck-Cre* and *Pvalb-FlpE* drivers should allow us to isolate the CCK/PVALB-double positive RGCs. Indeed, the *Cck-Cre*/*Pvalb-FlpE* combination effectively removed all the labeling from the INL (**Figures [6Aiv,viii](#F6){ref-type="fig"}**), as well as 98% of the labeling in the GCL (**Figures [6Aiii,vii](#F6){ref-type="fig"}**). Only two types of RGCs remained labeled: one type (80% of the sample) resembled on-alpha RGCs (**Figure [6Av](#F6){ref-type="fig"}**) and the other type (20% of the sample) resembled G4 ([@B4]) (**Figure [6Avi](#F6){ref-type="fig"}**).

In a second example, we created a *Pcp2-Cre*/*Pvalb-FlpE* intersection. The *Pcp2-Cre* driver predominantly targets bipolar cells ([@B23]) along with five types of RGCs: m-BGCs, s-BGCs, b-BGCs, on-DSGCs and ooDSGCs ([@B18]). Our analysis of *Pcp2-Cre* expression (**Figures [6Bi,ii](#F6){ref-type="fig"}**) is in agreement with previous reports. As expected, bipolar cell labeling was absent in the *Pcp2-Cre*/*Pvalb-FlpE* cross (**Figures [6Biv,viii](#F6){ref-type="fig"}**). Additionally, this combination also removed labeling from three out of five RGC types (m-BGCs, s-BGCs, b-BGCs) leaving only two types labeled: on-DSGCs and ooDSGC (**Figures [6Biii,vii](#F6){ref-type="fig"}**): two-thirds were on-off DSGCs (**Figure [6Bv](#F6){ref-type="fig"}**) versus one-third on-DSGCs (**Figure [6Bvi](#F6){ref-type="fig"}**).

In a third example, we crossed the *Pvalb-FlpE* and *Crh-Cre* drivers to isolate a population of CRH/PVALB-double positive RGCs. As demonstrated in previous studies, the *Crh-Cre* driver targeted at least three types of ACs ([@B30]) and three types of RGCs in the GCL (off-alpha RGCs, JAM-B RGCS and CRH-3 RGCs) ([@B41]), as well as a small number of ACs in the INL (**Figures [6Ci,ii](#F6){ref-type="fig"}**). The *Crh-Cre*/*Pvalb-FlpE* intersection removed labeling from the ACs in the GCL (**Figures [6Ciii,vii](#F6){ref-type="fig"}**) and the INL (**Figures [6Civ,viii](#F6){ref-type="fig"}**). Eventually, only two types of RGCs remained: more than 80% of the labeled cells belonged to off-alpha RGCs (CRH-1 RGCs, **Figure [6Cv](#F6){ref-type="fig"}**) while the rest were CRH-3 RGCs (**Figure [6Cvi](#F6){ref-type="fig"}**) ([@B41]).

### *Slc32a1-FlpO* Driver for Targeting AC Types

In contrast to the *Pvalb-FlpE* driver, the *Slc32a1-FlpO* driver only targeted ACs thus it could be used to remove labeling from both bipolar cells and RGCs. To test the effectiveness of the *Slc32a1-FlpO* driver in this application, we paired it with the *Cck-Cre* driver which broadly targets bipolar cells, ACs, Müller cells and RGCs (**Figures [6Di,ii](#F6){ref-type="fig"}**). As predicted, crossing *Slc32a1-FlpO* with *Cck-Cre* effectively removed labeling from bipolar and Müller cells in the INL, and only AC labeling remained (**Figures [6Div,vii](#F6){ref-type="fig"}**). In the GCL, all the RGC labeling was removed (**Figures [6Diii,vi](#F6){ref-type="fig"}**) and the remaining labeled ACs were all starburst as confirmed with ChAT antibody staining (**Figure [6Dv](#F6){ref-type="fig"}**), consistent with previous results ([@B41]).

The foregoing experiments demonstrated intersectional applications of two Flp drivers: *Pvalb-FlpE* and *Slc32a1-FlpO* with each crossed with different Cre drivers. Next, we reasoned that, if we applied *Pvalb-FlpE* intersection and *Slc32a1-FlpO* intersection in parallel, we could separately target ACs and RGCs in a same Cre driver for functional study. Here we chose the *Cart-Cre* driver. CART (Cocaine and amphetamine-regulated transcript) expresses in 15% of all RGCs as well as in a small group of ACs in the inner nuclear layer. It has been demonstrated that all CART-expressing RGCs are ooDSGCs ([@B20]; [@B29]). In the *Cart-Cre* driver, all the Cre-positive cells in the GCL were ooDSGCs, while the cells in the INL belonged to two types of ACs (**Figures [6Ei,ii](#F6){ref-type="fig"}**).

Crossing the *Cart-Cre* with the *Pvalb-FlpE* eliminated all the AC labeling (**Figures [6Eiv,vii](#F6){ref-type="fig"}**), leaving only ooDSGCs labeling in the GCL (**Figure [6Eiii](#F6){ref-type="fig"}**). On the other hand, crossing the *Cart-Cre* with the *Slc32a-FlpO* removed all the labeling from ooDSGCs (**Figures [6Ev,vii](#F6){ref-type="fig"}**), leaving only AC labeling in the INL (**Figure [6Evi](#F6){ref-type="fig"}**). This result demonstrates that intersectional strategies with the *Pvalb-FlpE* and *Slc32a1-FlpO* drivers can effectively lead to highly selective cell type-specific targeting in Cre lines driving expression in both ACs and RGCs.

### *Sst-FlpO* Driver for More Specific Targeting of AC and RGC Types

The *Sst-FlpO* driver targeted only three types of ACs. We reasoned if we could find a suitable Cre driver to pair with the *Sst-FlpO* driver, we could potentially reduce the number of targeted AC types. We selected the *Penk-Cre* driver which targeted Cre expression to multiple types of ACs in the INL (**Figure [6Fii](#F6){ref-type="fig"}**) and multiple types of ACs and RGCs in the GCL (**Figure [6Fi](#F6){ref-type="fig"}**). Interestingly, we found that when the *Penk-Cre* driver was crossed with *SST-FlpO* driver, highly specific targeting was achieved as the *Penk-Cre*/*Sst-FlpO* intersection mostly captured one type of ACs in the INL (**Figures [6Fiv,viii](#F6){ref-type="fig"}**) that appeared to be the SST-2 AC (**Figure [6Fvi](#F6){ref-type="fig"}**) and one type of RGCs in the GCL (**Figures [6Fiii,vii](#F6){ref-type="fig"}**) that resembled G14 RGC (**Figure [6Fv](#F6){ref-type="fig"}**) ([@B4]), although the labeling was rather sparse. **Table [3](#T3){ref-type="table"}** summarizes the AC and RGC types obtained from the intersectional strategies.

Screening of Flp Drivers for Their Expression in Retino-Recipient Regions
-------------------------------------------------------------------------

Finally, we examined FLP expression in the seven drivers in two major retino-recipient regions in the brain: the lateral geniculate nucleus (LGN) and the superior colliculus (SC) (**Figure [7](#F7){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**). FLP-expressing cells were labeled with tdTomato in *CMV-Cre*/*Flp*/*Ai65* mice. To mark retino-recipient zones, we performed intraocular injection of cholera toxin B conjugated to Alexa Fluor 488 (CTb-488), which fills RGC terminals via anterograde transport.

![Expression patterns of Flp drivers in the SC and the LGN. FLP-expressing cells were labeled with tdTomato (red) in *CMV-Cre;Flp;Ai65* mice. Retino-recipient zones were labeled with cholera toxin B conjugated to Alexa Fluor 488 (CTb-488) (green) injected to the eyes. **(A)** *Pvalb-FlpE* driver. In the SC, FLPe strongly expressed in the deep layer (**ii**, blue arrow) but sparsely expressed in the superficial layer (**ii**, white arrow). The middle layer of vLGN also strongly expressed FLPe (**i**, blue arrow). The dLGN showed very sparse labeling (**i**, white arrows). Intense tdTomato background comes from axons of FLPe^+^ RGCs. **(B)** *Sst-FlpO* driver. Strong FLPo expression was found in the deep layer of the SC (**ii**, blue arrow). Only sparse labeling was found in the vLGN and dLGN, while most of the labeled cells were in the superficial layer (**i**, white arrow for dLGN, blue arrow for vLGN). There was also moderate labeling in IGL (yellow arrow). **(C)** *Slc32a1-FlpO* targeted FLPo expression broadly to all the layers in the LGN and SC. **(D)** *Dlx5/6-FlpO* driver. FLPo expression was sparse and restricted primarily to the superficial (**i**, white arrow) and middle layer of the vLGN (**i**, blue arrow). No FLPo labeling was found in SC and dLGN. **(E)** *Nkx2-FlpO* driver. In the dLGN, sparely labeled cells were found in the core region (**i**, arrow). There was no labeling in other areas. **(F)** *Rorb-FlpO* driver. FLPo expression was observed in neurons in all layers in the SC **(ii)**, as well as glial cells in the entire LGN including both the dLGN and the vLGN **(i)**. **(G)** *Vip-FlpO* driver did not express in either the LGN or the SC. For each driver, examples of enlarged labeling area are shown on the right. Scale bar: 100 μm for the LGN, 50 μm for the SC, 20 μm for the enlarged regions.](fncir-12-00066-g007){#F7}

###### 

FLP expression in the dLGN and the SC in Flp drivers.

  Flp driver       dLGN                    SC
  ---------------- ----------------------- ------------------------------------------
  *Pvalb-FlpE*     shell (+), core (+)     Deep layer (*++)*, superficial layer (+)
  *Sst-FlpO*       shell (+)               Deep layer (++)
  *Slc32a1-FlpO*   shell (++), core (++)   Deep layer (++), superficial layer (++)
  *Rorb-FlpO*      Glial cells             Deep layer (++), superficial layer (++)
  *Nkx2-FlpO*      Core (+)                None
  *Dlx5/6-FlpE*    None                    None
  *Vip-FlpO*       None                    None

++, Strong expression; +, sparse expression

.

In the *Pvalb-FlpE* driver, we observed prominent FLP expression in the deep layer of the SC but sparse expression in the superficial layer of the SC (**Figure [7Aii](#F7){ref-type="fig"}**). The middle layer of the vLGN also showed strong labeling (**Figure [7Ai](#F7){ref-type="fig"}**). However, only very sparse labeling was detected in both the shell and the core of the dLGN (**Figure [7Ai](#F7){ref-type="fig"}**). Note that *Pvalb-FlpE* targeted many RGCs whose axonal processes contributed to the strong tdTomato background in the image shown. In the *Sst-FlpO* driver, strong FLPo expression was found in the deep layer of the SC (**Figure [7Bii](#F7){ref-type="fig"}**). Sparse labeling was found in the vLGN and dLGN, with most of the labeled cells located in the superficial layer (**Figure [7Bi](#F7){ref-type="fig"}**). Interestingly, there was moderate labeling in the IGL in the *Sst-Flp* driver (**Figure [7Bi](#F7){ref-type="fig"}**). In the *Slc32a1-FlpO* driver, strong FLPo expression was observed in all layers in the dLGN, vLGN, and SC (**Figures [7Ci,ii](#F7){ref-type="fig"}**). In the *Dlx5/6-FlpE* driver, FLPe expression was restricted to the superficial and middle layers of the vLGN (**Figure [7Di](#F7){ref-type="fig"}**). No FLPo labeling was found in the SC and the dLGN (**Figures [7Di,ii](#F7){ref-type="fig"}**). In the *NKx2-FlpO* driver, neurons expressing the tdTomato reporter were only detected in the dLGN where they were sparely distributed within the core region (**Figure [7Ei](#F7){ref-type="fig"}**), no FLPo expression was detected in the SC (**Figure [7Eii](#F7){ref-type="fig"}**). In the *Rorb-FlpO* driver, FLPo expression targeted neurons in the SC (**Figure [7Fii](#F7){ref-type="fig"}**) and glial cells in the entire LGN including both the dLGN and the vLGN (**Figure [7Fi](#F7){ref-type="fig"}**). In the *Vip-FlpO* driver, no FLPo expression was observed in either the LGN or the SC (**Figure [7G](#F7){ref-type="fig"}**).

In summary, the SC labeling was observed from four lines: *Pvalb-FlpO* (all layers), *Sst-FlpO* (deep layer), *Slc32a1-FlpO* (all layers) and *Rorb-FlpO* (all layers). Meanwhile, dLGN labeling was observed in four lines: *Pvalb-FlpE* (shell and core), *Sst-FlpO* (shell), *Slc32a1-FlpO* (shell and core) and *NKx2-FlpO* (core). Finally, vLGN labeling was observed in four lines: *Pvalb-FlpE* (middle layer), *Sst-FlpO* (superficial layer) *Slc32a1-FlpO* (all layers) and *Dlx5/6-FlpE* (superficial layer and middle layer).

Discussion
==========

As in many other brain circuits, there are two major challenges for dissecting retinal circuits: ([@B8]) to increase the specificity of cell-type targeting and ([@B27]) to discover new cell types involved in the circuits. Here we used an intersectional strategy, specifically the combination of Cre/LoxP and Flp/FRT systems, to increase the specificity for targeting amacrine and ganglion cell types in the mouse retina. The Flp-FRT system carries out site-specific recombination similar to the Cre-loxP system, however the efficiency of recombination mediated by the wild type Flp recombinase is lower than that of Cre. Consequently Cre/loxP was initially chosen as the main genetic site-specific recombination system, leading to the development of hundreds of Cre driver lines over the past two decades ([@B13]). To improve the Flp-FRT system, a thermostable derivative of wild type Flp, FlpE (enhanced Flp), was developed and was further codon-optimized (named FlpO) ([@B6]; [@B11]). These improvements made the Flp/FRT and Cre/loxP systems equally efficient for mouse genetic manipulations. Consequently, the last several years have seen the creation of increasing numbers of Flp lines, a trend that is expected to continue. Thus, we expect that strategies that we have tested here will have even greater applicability in the future.

Two parallel approaches could be used to facilitate the identification of suitable pairs of Cre and Flp drivers for intersection. First, information from transcriptome studies and protein expression profiling studies can be used to identify gene specific markers for retinal cell types/subtypes. In recent years, RNA sequencing (RNA-Seq)-based transcriptome analysis has begun to transform the study of the gene expression in the retina field ([@B37]; [@B24]; [@B36]; [@B32]). *In silico* data mining will allow us to select candidate genes whose promoters can be used to construct appropriate Cre lines and Flp lines. However, these mice are likely not available yet. In addition, due to the complex nature of gene expression, it is often unsurprising that transgene expression in a given transgenic mouse line or knock-in mouse line differ from endogenous gene expression. An alternative approach is to screen the available Cre and Flp drivers, and then select the appropriate pair with overlapped cell types. Given the limited information about the genetic profiling of many retinal cells and the limited number of available Flp drivers, we think the most straightforward approach at this stage is to screen the available Flp drivers so as to provide a base for future intersectional crossing with the appropriate Cre lines.

Since an intersectional approach is relatively new in retinal research, it is important to validate the feasibility of this strategy for targeting subpopulations of retinal cell types. Our experiments demonstrated two major advances for targeting retinal cells. First, intersections can be used to eliminate (or select for) whole classes of cells (i.e., ACs or RCGs). For example, the *Pvalb-FlpE* driver exclusively targets RGC types, thus it can be used to remove labeling from non-RGC types in the Cre/Flp intersection. In this study, we crossed *Pvalb-FlpE* lines with *Cck-Cre*, *Pcp2-Cre*, *Crh-Cre* and *Cart-Cre* drivers. In all cases, we found that only RGCs were selectively labeled while non-RGC labeling was removed. Conversely, we selected a *Slc32a1-FlpO* driver to eliminate non-AC labeling as the *Slc32a1-FlpO* driver only targeted ACs. Indeed when the *Slc32a1-FlpO* driver was paired with a *Cck-Cre* driver or a *Cart-Cre* driver, all non-AC labeling was effectively removed. Thus we have demonstrated that an intersectional strategy works to eliminate labeling from whole classes of cells. It is important to note that while *Pvalb-FlpE* only targets certain RCG types, it does not cover all of the RGCs. Therefore crossing Cre drivers with *Pvalb-FlpE* will filter out not only the non-RGC cells but also many RGCs not covered by *Pvalb-FlpE*. The *Slc32a1-FlpO* driver, on the other hand, targets more than 95% of ACs. Thus, a vast majority of the ACs targeted in Cre drivers will remain when crossed with the *Slc32a1-FlpO* driver.

The second advance of the intersectional strategy is the high selectivity that can be achieved. Our intersectional breedings have routinely removed more than 90% of the cells in Cre drivers, and lead to handful cell types remaining in the intersection. When crossing *Pvalb-FlpE* with *Cck-Cre*, *Pcp2-Cre*, *Crh-Cre* or *Cart-Cre*, we were able to isolate only one to three types of RGCs, which represents a big improvement compared with most existing Cre lines ([@B41]; [@B26]). A more striking example came from the *Penk-Cre*/*Sst-FlpO* intersection which removed most cell types in the *Penk-Cre* driver and narrowed cell types down to mainly just one type of AC in the INL and one type of RGC in the GCL. By selecting appropriate pairs of Cre and Flp drivers for crossing, an intersectional strategy holds out the possibility of labeling, or introducing opto- and chemo-genetic manipulations into only a single type.

A present-day weakness of our approach is that Flp drivers for targeting more specific cell types, in particular, the AC types, are still lacking, except for *Vip-FlpO* and *Sst-FlpO*. Future development of Flp drivers to target more specific ACs will greatly benefit the functional characterization of AC types, the least well characterized cell class in the retina. The prevalence of mouse lines that report the presence of two recombinases is also an issue. Several reporter mouse lines for delivering fluorescent markers and genetic tools are available, including Ai65 for tdTomato and Ai80 for calcium translocating channelrhodopsin (CatCh, JAX025109). Further development of reporter lines for other genetically encoded sensors and effectors, such as GCaMP, iGluSnFr and DREADDs, will greatly facilitate various ways of observing and manipulating functions of cell types in the Cre/Flp intersection.

Beyond enhancing the specificity for cell type targeting, intersectional strategies also provide a powerful platform for discovering new cell types. Identifying AC types and completing the anatomical catalog for this major class of retinal interneuron has been a long-term challenge. Judiciously chosen intersections restrict the number of targeted cell types and can greatly reduce the density of cell labeling. This reduction allows us to tease apart the intermingled neuron networks in the IPL making it easier to anatomically identify new cell types. By introducing reporter mouse lines ([@B25]) and viral vectors ([@B12]; [@B25]; [@B15]), genetically encoded calcium indicators and optogenetic effectors can be delivered to these new cells for systematic functional analysis.
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